Mineral (Mal)Adaptation to kidney disease—Young investigator award address: American society of nephrology kidney week 2014

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 10, 2015, Pages 1875-1885

  Wolf, Myles ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; PHOSPHATE;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; END STAGE RENAL DISEASE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MINERAL ADAPTATION; MINERAL METABOLISM; ADAPTATION; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; HOMEOSTASIS; HYPERPHOSPHATEMIA; METABOLISM; PATHOPHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; BIOMARKERS; CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84943791975     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04430415     Document Type: Article

References (84)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
3. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
4. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
5. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006
6. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007
7. Murer H, Hernando N, Forster I, Biber J: Proximal tubular phosphate reabsorption: Molecularmechanisms. Physiol Rev 80: 1373-1409, 2000
8. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
9. Craver L, Marco MP, Martínez I, Rue M, Borràs M,Martín ML, SarróF, Valdivielso JM, Fernández E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5- achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171-1176, 2007
10. Isakova T, Wahl P, Vargas GS, Gutié rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
11. Slatopolsky E, Gradowska L, Kashemsant C, Keltner R, Manley C, Bricker NS: The control of phosphate excretion in uremia. J Clin Invest 45: 672-677, 1966
12. Prié D, Urena Torres P, Friedlander G: Latest findings in phosphate homeostasis. Kidney Int 75: 882-889, 2009
13. Slatopolsky E, Robson AM, Elkan I, Bricker NS: Control of phosphate excretion in uremic man. J Clin Invest 47: 1865-1874, 1968
14. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, BrickerNS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 2: 147-151, 1972
15. Portale AA, Booth BE, Halloran BP, Morris RC Jr: Effect of dietary phosphorus on circulating concentrations of 1,25- dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 1580-1589, 1984
16. Carpenter TO: The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30: 1-9, 2012
17. ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000
18. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
19. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Jüppner H, Econs MJ: The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86: 497-500, 2001
20. De Beur SM, Finnegan RB,Vassiliadis J, Cook B, BarberioD, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC: Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17: 1102-1110, 2002
21. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.NEngl JMed348: 1656-1663, 2003
22. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561- 568, 2004
23. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
24. Kempson SA, Lö tscher M, Kaissling B, Biber J, Murer H, Levi M: Parathyroid hormone action on phosphate transportermRNAand protein in rat renal proximal tubules. Am J Physiol 268: F784- F791, 1995
25. Saito H,Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N: Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005
26. Bai XY, Miao D, Goltzman D, Karaplis AC: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem278: 9843-9849, 2003
27. Shigematsu T, Horiuchi N, Ogura Y, Miyahara T, Suda T: Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-hydroxyvitamin D3 by a mechanism involving adenosine 39,59-monophosphate in rats. Endocrinology 118: 1583-1589, 1986
28. Ferrari SL, Bonjour J-P, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005
29. Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS: Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006
30. Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 3144-3149, 2006
31. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79: 112-119, 2011
32. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006
33. Isakova T,GutierrezO, Shah A, Castaldo L,Holmes J, Lee H,Wolf M: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008
34. Scanni R, vonRotz M, Jehle S, Hulter HN, Krapf R: The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol 25: 2730-2739, 2014
35. Lavi-Moshayoff V,Wasserman G,Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high- FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
36. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T: Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005
37. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez- Moreno JM, Ramírez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, Felsenfeld A, Almaden Y: Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23: 1190-1197, 2012
38. David V, Dai B, Martin A, Huang J, Han X, Quarles LD: Calcium regulates FGF-23 expression in bone. Endocrinology 154: 4469- 4482, 2013
39. Kuro-oM,Matsumura Y, AizawaH, KawaguchiH, Suga T, Utsugi T, Ohyama Y, KurabayashiM, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI:Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
40. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006
41. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
42. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44: 250-256, 2004
43. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, HammLL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) study: design and methods. J Am Soc Nephrol 14 [Suppl 2]: S148-S153, 2003
44. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
45. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435, 2010
46. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003
47. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
48. Gutié rrezOM,Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
49. Isakova T, Xie H, YangW, Xie D, Anderson AH, Scialla J,Wahl P, Gutié rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
50. Kendrick J, Cheung AK, Kaufman JS,Greene T, RobertsWL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
51. BrandenburgVM, KleberME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H: Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 237: 53-59, 2014
52. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 60: 200-207, 2012
53. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, YangW, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349-360, 2014
54. Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, FliserD,HeineGH: Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 9: 1049-1058, 2014
55. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4 [Suppl 1]: S79-S91, 2009
56. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989
57. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the FraminghamHeart Study.NEngl JMed 322: 1561-1566, 1990
58. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The Cardiovascular Health Study. J Am Coll Cardiol 43: 2207-2215, 2004
59. Gutié rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R,Wang TJ, deFilippi C,Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552, 2009
60. Corda S, Mebazaa A, Gandolfini MP, Fitting C, Marotte F, Peynet J, Charlemagne D, Cavaillon JM, Payen D, Rappaport L, Samuel JL: Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ Res 81: 679-687, 1997
61. Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 85: 507-514, 1990
62. Scheinowitz M, Kotlyar A, Zimand S, OhadD, Leibovitz I, Bloom N, Goldberg I, Nass D, Engelberg S, Savion N, Eldar M: Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Exp Physiol 83: 585-593, 1998
63. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutié rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J,Go AS, Rosas SE,Nessel L, Townsend RR, Feldman HI, St John SuttonM,Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
64. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551, 2009
65. Jovanovich A, Ix JH,Gottdiener J,McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M: Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231: 114-119, 2013
66. Frey N, Olson EN: Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 65: 45-79, 2003
67. Di MarcoGS, Reuter S, KentrupD,Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstädt H, Wolf M, Faul C, Brand M: Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 29: 2028-2035, 2014
68. Shalhoub V, Shatzen EM,Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N,WangW, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122: 2543-2553, 2012
69. Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2: 1241-1248, 2007
70. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA; European Uremic Toxin (EUTox) Work Group: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23: 2017-2025, 2012
71. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M; Chronic Renal Insufficiency Cohort Study Investigators: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83: 1159-1168, 2013
72. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17, 2000
73. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20: 381-387, 2009
74. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
75. Gué rin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
76. Scialla JJ, Wolf M: Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10: 268- 278, 2014
77. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22: 124-136, 2011
78. Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C, Taniguchi M,Wolf M, Brand M, TakahashiM, Kuro-O M, Hill JA, Moe OW: Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 26: 1290-1302, 2015
79. Gutié rrez OM: Sodium- and phosphorus-based food additives: Persistent but surmountable hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis 20: 150-156, 2013
80. Gutié rrez OM, Anderson C, Isakova T, Scialla J, Negrea L, Anderson AH, Bellovich K, Chen J, Robinson N, Ojo A, Lash J, Feldman HI, Wolf M; CRIC Study Group: Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol 21: 1953-1960, 2010
81. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR: Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J AmSoc Nephrol 6: 257-264, 2011
82. Isakova T, Gutié rrezOM, Smith K, EpsteinM, Keating LK, Jüppner H, Wolf M: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26: 584-591, 2011
83. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutié rrez OM, Diego J, Lenz O, Contreras G, Mendez A,Weiner RB,Wolf M: Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 8: 1009-1018, 2013
84. Faul C: Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 21: 369-375, 2012